Related Experiment Video
Updated: Jan 9, 2026
06:14
Translational Rabbit Model of Chronic Cardiac Pacing
Published on: January 6, 2023
3.1K
Leadless Pacemakers in Complex Congenital Heart Disease
Archana Rao1, Elen Hughes1, Milos Prica1
1Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK.
Journal of Clinical Medicine
|December 11, 2025
Summary
Leadless pacemakers offer a safer alternative for complex congenital heart disease patients, overcoming challenges associated with traditional pacing systems and their long-term complications.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Traditional pacing in complex congenital heart disease (CCHD) presents significant challenges, including infection risks and vascular lead complications.
- Existing pacing methods in CCHD often have drawbacks impacting patient safety and long-term outcomes.
Purpose of the Study:
- To review the current landscape of leadless pacemaker technology.
- To evaluate the existing evidence for leadless pacemakers in CCHD.
- To explore the potential application of leadless pacemakers in CCHD management.
Main Methods:
- Literature review of current leadless pacemaker technology.
- Analysis of published studies on leadless pacing in congenital heart conditions.
- Synthesis of evidence regarding safety and efficacy in complex cardiac anatomies.
Main Results:
- Leadless pacemakers demonstrate a strong safety and efficacy profile in standard cardiac anatomy.
- Limited but emerging evidence suggests potential utility in specific CCHD scenarios.
- Further research is needed to fully establish their role in CCHD.
Conclusions:
- Leadless pacemakers represent a promising advancement for pacing in CCHD.
- They may mitigate risks associated with transvenous leads in this population.
- Future studies should focus on expanding their application and long-term outcomes in CCHD.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
01:26Mitral Stenosis III: Medical Management
220
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
220
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
362
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362
01:22Mitral Stenosis I: Introduction
386
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
386
01:30Cardiomyopathy II: Dilated Cardiomyopathy
436
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K